amikacin has been researched along with Pleuropneumonia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Apter, S; Eviatar, T; Grossman, E; Hoffman, C; Keller, N; Rosman, Y; Thaler, M | 1 |
| Atassi, K; Bassinet, L; Honoré, I; Housset, B; Jabot, L; Maître, B; Mangiapan, G; Monnet, I; Schubel, K | 1 |
2 other study(ies) available for amikacin and Pleuropneumonia
| Article | Year |
|---|---|
Nocardiosis: a 15-year experience in a tertiary medical center in Israel.
Topics: Adrenal Cortex Hormones; Adult; Aged; Amikacin; Carbapenems; Ceftriaxone; Cohort Studies; Encephalitis; Female; Humans; Immunocompromised Host; Israel; Male; Middle Aged; Nocardia Infections; Pleuropneumonia; Retrospective Studies; Risk Factors; Skin Diseases, Bacterial; Soft Tissue Infections; Tertiary Care Centers; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2013 |
[Pleuropneumonia due to Mycobacterium chelonae].
Topics: Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bronchiectasis; Clarithromycin; Drainage; Drug Therapy, Combination; Humans; Male; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Pleuropneumonia; Risk Factors; Treatment Outcome | 2011 |